Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of DFP-14323 plus afatinib versus afatinib in NSCLC with uncommon EGFR mutations
jRCT2061230111Phase 3Recruiting
- Sponsor
- Delta-Fly Pharma, Inc.
- Start
- Jul 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ubenimex and afatinib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Delta-Fly Pharma, Inc. Primary endpoint: Progression-free survival by blinded independent central review. Started Jul 2024; status: recruiting.
02
Drugs
ubenimexafatinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on jRCT2061230111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230111.